Thursday, April 11, 2019, Anaheim, California, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the ONS 44th Annual Congress

PART 3 — Locally Advanced Non-Small Cell Lung Cancer

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room:
Grand Ballroom E-K (Lobby Level)
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Edward B Garon, MD, MS
Associate Professor
Director, Thoracic Oncology Program
Director, Signal Transduction and Therapeutics Research Program
David Geffen School of Medicine at UCLA
Jonsson Comprehensive Cancer Center
Los Angeles, California

Matthew Gubens, MD, MS
Associate Professor, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Blanca Ledezma, MSN, NP
Nurse Practitioner
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Wendi S Lee, MSN, RN, NP-C
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP during the Oncology Nursing Society’s (ONS) 44th Annual Congress, April 11-14, 2019 in Anaheim, California. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
5:30 AM – 6:00 AM — Registration and Breakfast Buffet
6:00 AM – 7:30 AM — Educational Program

Module 1: Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting


  • Staging and workup for patients with newly diagnosed NSCLC; overall prognosis of Stage IIIA versus Stage IIIB disease
  • Management of Stage IIIA NSCLC in patients who are fit for surgery; role of postoperative radiation therapy and chemotherapy in these individuals
  • Contraindications to surgery in patients presenting with Stage IIIA or IIIB NSCLC; rationale for and available research guiding the use of definitive concurrent chemotherapy and radiation therapy for patients with unresectable Stage IIIA/B disease
  • Historical outcomes associated with standard concurrent chemoradiation therapy and consolidation chemotherapy in patients with unresectable Stage III disease
  • Biologic rationale for the evaluation of immune checkpoint inhibition for patients with Stage III disease undergoing chemoradiation therapy; preclinical work supporting the synergistic effect between chemoradiation therapy and immune checkpoint inhibitors

Module 2: Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease


  • Rationale for and design of the Phase III PACIFIC trial examining the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Key efficacy findings from the PACIFIC trial; effect of consolidation durvalumab on response rate, progression-free survival and overall survival
  • Patient selection for and practical implementation of sequential durvalumab in the management of unresectable Stage III NSCLC
  • Efficacy and current role of durvalumab in prespecified subgroups (eg, histology, smoking status, PD-L1 status, disease with a targetable genomic alteration)
  • Optimal timing for the use of durvalumab consolidation; impact of underlying radiation therapy-induced toxicities (eg, pneumonitis, esophagitis) on the potential introduction of durvalumab consolidation therapy in this setting
  • Clinical and biologic factors affecting the selection of subsequent therapies in patients who have received consolidation durvalumab and experienced disease progression

Module 3: Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease


  • Mechanisms underlying immune-related adverse events associated with immune checkpoint inhibitor therapy
  • Rates of Grade 3/4 adverse events, including pneumonitis and other immune-mediated toxicities, and treatment discontinuation among patients receiving durvalumab in the PACIFIC study
  • Optimal monitoring of patients receiving consolidation durvalumab for the presence of immune-mediated adverse events; supportive care protocols and indications for withholding or permanently discontinuing therapy
  • Counseling patients receiving immune checkpoint inhibitor therapy on the potential for immune-related adverse events; available resources to assist clinicians and patients with regard to the identification and management of these toxicities
  • Effects of immune-directed therapies in patients with prior autoimmune diseases or who have undergone solid organ transplant

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:

  • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced non-small cell lung cancer (NSCLC), and consider this information when counseling patients regarding therapeutic recommendations.
  • Appreciate available research data documenting the benefits and risks of sequential anti-PD-L1 antibody therapy for patients with unresectable locally advanced NSCLC.
  • Review the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and/or manage these toxicities.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CME/CNE planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Anaheim Marriott
700 West Convention Way
Anaheim, CA 92802
Hotel Phone: (714) 750-8000

Meeting Room: 
Grand Ballroom E-K (Lobby Level)

The Anaheim Marriott is the headquarters hotel for the 2019 ONS Congress and is conveniently located near the Anaheim Convention Center (0.2 miles).


Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 3 — Locally Advanced Non-Small Cell Lung Cancer. Onsite registration will be open starting at 5:30 AM on Thursday, April 11, 2019. If you are interested in standing by for seating (day of the program), please visit our onsite registration desk located outside the Grand Ballroom (Lobby Level) at the Anaheim Marriott hotel (700 West Convention Way, Anaheim, CA 92802). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis prioritized for oncology nurses treating patients. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.